Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society
April 19 2018 - 7:00AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical
company focused on developing and commercializing novel antibiotics
to treat life-threatening multidrug-resistant (MDR) infections,
today announced two data presentations at the 38th Annual Meeting
of the Surgical Infection Society (SIS), taking place April 22-25,
at the Four Seasons in Westlake Village, CA. Presentations will
include information about the Company’s lead drug candidate,
eravacycline, which is in development for the treatment of
complicated intra-abdominal infections (cIAI).
“Data presented at SIS’s Annual Meeting demonstrate
eravacycline’s potent in vitro activity from a total of 7,815
single-patient clinical isolates collected during a four-year
period from U.S. hospitals,” said Guy Macdonald, President and
Chief Executive Officer of Tetraphase Pharmaceuticals.
“Eravacycline was two- to four-fold more active than tigecycline
against most of the Gram-negative and Gram-positive clinical
isolates including multidrug-resistant strains, supporting our
belief that eravacycline offers a clear advantage in institutions
where Gram-negative resistance is a problem.”
Mr. Macdonald added, “In another presentation, we examined the
outcomes of the length of therapy in patients receiving
eravacycline and meropenem for cIAI. Findings showed that a shorter
course of treatment with eravacycline is associated with outcomes
similar to those of a longer course of therapy, suggesting that the
current treatment prescribing paradigm of antibiotics may have room
to evolve.”
The details for the data presentations at SIS are as
follows:
Poster Title: Length of therapy during a
phase 3 study of eravacycline and meropenem for complicated
intra-abdominal infectionDate and time: Wednesday,
April 25 from 3:30 – 5:30 p.m. PTLocation:
Ballroom APoster number: ACS-MO10Session
information: Moderated Oral ePoster Session I - Session II
- Ballroom A, Ballroom E, Ventura & Sherwood
Poster Title: Surveillance of the in
vitro activity of eravacycline and comparators against clinical
isolates from the U.S. from 2013-2016 Date and
time: Wednesday, April 25 from 3:30 – 5:30 p.m.
PTLocation: Sherwood Poster
number: Global-MO11Session information:
Moderated Oral ePoster Session I - Session II - Ballroom A,
Ballroom E, Ventura & Sherwood
Full abstracts can be found on the SIS website at
www.sisna.org.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a biopharmaceutical company using its
proprietary chemistry technology to create novel antibiotics for
serious and life-threatening bacterial infections, including those
caused by many of the MDR bacteria highlighted as urgent public
health threats by the Centers for Disease and Control. The Company
has created more than 3,000 novel tetracycline analogs using its
proprietary technology platform. Tetraphase's pipeline includes
three antibiotic clinical candidates: eravacycline, which has
completed phase 3 clinical trials and is under review for potential
approval in complicated intra-abdominal infections by the U.S. Food
and Drug Administration and the European Medicines Agency, and
TP-271 and TP-6076, which are in phase 1 clinical trials.
Eravacycline is an investigational product only and has not been
approved for commercialization. Please visit www.tphase.com for
more Company information.
Forward-Looking StatementsAny statements in
this press release about our future expectations, plans and
prospects, including statements regarding our strategy, future
operations, prospects, plans and objectives, and other statements
containing the words "anticipates," "believes," "expects," "plans,"
"will" and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: whether the Company's regulatory
submission will receive approval from the United States Food and
Drug Administration or equivalent foreign regulatory agencies;
whether, if any clinical candidate, including eravacycline obtains
approval, it will be used in the hospital setting to treat patients
or otherwise successfully distributed and marketed; and other
factors discussed in the "Risk Factors" section of our Annual
Report for the year ended December 31, 2017 on Form 10-K, filed
with the Securities and Exchange Commission on March 6, 2018. In
addition, the forward-looking statements included in this press
release represent our views as of April 19, 2018. We anticipate
that subsequent events and developments will cause our views to
change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so.
Investor Contacts:Tetraphase
Pharmaceuticals
Jennifer Vierajviera@tphase.com 617-600-7040
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Sep 2023 to Sep 2024